Insider Transactions in Q2 2022 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2022
|
Corazon (Corsee) D. Sanders |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+31.44%
|
-
|
|
Jun 24
2022
|
Deborah Dunsire |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+17.21%
|
-
|
|
Jun 24
2022
|
Shehnaaz Suliman |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+23.09%
|
-
|
|
Jun 24
2022
|
Amrit Ray |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+28.16%
|
-
|
|
Jun 24
2022
|
Michael Narachi |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+15.68%
|
-
|
|
Jun 24
2022
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+11.08%
|
-
|
|
Jun 24
2022
|
Lars Ekman Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+15.68%
|
-
|
|
Jun 24
2022
|
Daniel G Welch |
BUY
Grant, award, or other acquisition
|
Direct |
3,300
+15.68%
|
-
|
|
Jun 19
2022
|
Erik Harris EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
295
-0.81%
|
$15,930
$54.78 P/Share
|
|
Apr 19
2022
|
Amrit Ray |
BUY
Grant, award, or other acquisition
|
Direct |
5,120
+50.0%
|
-
|
|
Apr 16
2022
|
Theodore Alan Huizenga SVP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
132
-0.77%
|
$11,088
$84.55 P/Share
|